Amoy Diagnostics Co., Ltd.

Shenzhen Stock Exchange 300685.SZ

Amoy Diagnostics Co., Ltd. EBIT Margin for the year ending December 31, 2023: 28.37%

Amoy Diagnostics Co., Ltd. EBIT Margin is 28.37% for the year ending December 31, 2023, a -19.65% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Amoy Diagnostics Co., Ltd. EBIT Margin for the year ending December 31, 2022 was 35.31%, a 28.70% change year over year.
Amoy Diagnostics Co., Ltd. EBIT Margin for the year ending December 31, 2021 was 27.44%, a -0.37% change year over year.
Amoy Diagnostics Co., Ltd. EBIT Margin for the year ending December 31, 2020 was 27.54%, a -5.11% change year over year.
Amoy Diagnostics Co., Ltd. EBIT Margin for the year ending December 31, 2019 was 29.02%, a -10.25% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

Shenzhen Stock Exchange: 300685.SZ

Amoy Diagnostics Co., Ltd.

CEO	Ms. Ying Chen
IPO Date	Aug. 3, 2017
Location	China
Headquarters	39 Dingshan Road
Employees	1,119
Sector	Healthcare
Industries Biotechnology

Description

Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on molecular diagnostics for oncology precision medicine in China and internationally. The company offers NGS, real-time PCR, FISH, and extraction assays. Amoy Diagnostics Co., Ltd. was founded in 2008 and is based in Xiamen, China.

Key trends

Past 5 years